Allegheny University of the Health Sciences (1994–1998) was a medical school in Philadelphia that was formed in 1994 through a merger of the Medical College of Pennsylvania (MCP) and Hahnemann University. As part of MCP Hahnemann School of Medicine, the largest private medical school in the United States, Allegheny University was under the new University of the Health Sciences, which also included schools for allied medical disciplines. Prior to the merger, the Medical College of Pennsylvania had been the first medical school to be purchased by a hospital (Pittsburgh's Allegheny General Hospital). The new university and other hospitals all were units of the Allegheny Health, Education and Research Foundation (AHERF).

Gene Trak Systems, part of Neogen Corp., is an American company. The firm provides food testing services with innovative DNA probe-based products for bacterial contaminants. It was acquired by Neogen Corp. from Abbott Molecular, Inc. on August 06, 2001 for $3.50 million.

Kookmin University Industry-Academic Cooperation is an independent academic corporation.

Alexon Biomedical, Inc. is a private company headquartered in Mounten View, CA. The firm manufactures pharmaceutical products.

The Institut national de la recherche agronomique (INRA, pronounced [inʁa]; English: National Institute of Agricultural Research) is a French public research institute dedicated to agricultural science. It was founded in 1946 and is a Public Scientific and Technical Research Establishment under the joint authority of the Ministries of Research and Agriculture.

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections. With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and finished dosage forms (FDF), and the world-leading supplier of Vancomycin and Colistimethate Sodium (CMS). Our range of anti-infective treatments combat, most types of bacterial and antibiotic-resistant infections and certain fungal diseases. We have growing sales in more than 70 countries to over 700 customers and are continually developing and expanding our product range to meet new treatment needs and to better service our customers’ requirements. This includes developing new dosage forms using Xellia’s APIs, and if required APIs sourced from our network of suppliers. To complement our dry powder fill and freeze-dried vials for injectable delivery we are also developing innovative proprietary delivery systems and formulations for topical, inhaled or injectable administration either in house or through partnerships. We also offer contract manufacturing services and custom synthesis for clinical trial material supply. Xellia is a private company, with more than 850 employees and four state-of-the-art manufacturing facilities in Norway, Denmark, Hungary and China. We operate according to current Good Manufacturing Practice (cGMP) and our facilities have received regulatory approval from all relevant authorities, including the US Food and Drug Administration (FDA). Our operational headquarters are in Copenhagen, Denmark.

Bioneer is a biotech company that develops molecular biology products and technologies including oligonucleotides, thermostable polymerases, and instruments of gene manipulation. From its inception, Bioneer has invested in the integration of recombinant DNA technology, fermentation, biochemistry and nucleic acid chemistry in addition to mechanics, photonics and electronics. The company is positioned to fully-integrate its capability to develop next-generation technologies in the post-genome era through the invention of new biochemistry and instruments. Bioneer was established in 1992 and is based in Daejeon, South Korea.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Apothekernes Laboratorium AS is a private company headquartered in Oslo, Norway, that manufactures Medicinal and Botanical products.

Vysis develops, commercializes and markets clinical products that provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The Company has assembled a management team experienced in developing,commercializing and marketing DNA based diagnostic products and associated genetic workstations. The Company was the first to obtain Food and Drug Administration ("FDA") clearance for a genomic product using fluorescence INSITU hybridization ("FISH"). Vysis currently markets four FDA cleared clinical products in addition to distributing over 240 research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 28 countries. It has an installed base of over 320 proprietary genetic workstations at 224 laboratories in 18 countries. The Company has a pipeline of nine clinical products under development and an expanding list of clinical product leads based upon its collaborations with leading medical research institutions, which include the University of California, San Francisco, the Mayo Clinic, St. Jude Children's Research Hospital, the University of Chicago and the Reproductive Genetics Institute.

Bioneer is a Danish advanced technology company, providing custom development- and analytical services to projects in drug development- and diagnostic companies, academic groups and hospitals. Bioneer is highly specialized within applications of cells, using their extensive knowledge anywhere from disease modeling using pluripotent stem cells and human primary cells; to recombinant protein production and biomarker identification/validation (RNA, DNA, protein) in single-cell- and tissue preparations. Furthermore, Bioneer also offers drug development of small molecules and biologics, from characterization through to a final formulation.

Morvus Technology Ltd., a pharmaceutical company, engages in the discovery, development, and commercialization of drugs and technologies in the oncology field. Its clinical candidates include MTL-005, a therapy for cancers treated with conventional radiotherapy; MTL-007, a novel anti-cancer prodrug; and MTL-003, an anti-angiogenic cancer therapy. The company's research portfolio comprises MorTar platform technology that identifies new proteins and genes that share the ability to inhibit apoptosis; HAI-X, an anti-angiogenic treatment for prostate cancer; and MorGen, a novel prodrug-activating system. The company also engages in the development of anti-cancer treatments using genetic modification techniques. In addition, it offers MorAnt, an anti-parasitic drug; and MorRid, a rodenticide. Morvus Technology Ltd. was founded in 2004 and is based in Carmarthen, the United Kingdom.

Wuhan Baitai Genetic Engineering Co., Ltd., established on 2009-10-09, Business scope includes research and development of genetic and molecular diagnostic reagents;Biotechnology,Product development.(Items subject to examination and approval under special state-owned regulations in the above-mentioned business scope,After approval or with a valid license to operate);Three categories of medical devices:6840Production of clinical laboratory analysis instruments and in vitro diagnostic reagents and sales of self-produced products;No.I,II,IIIWholesale and retail of similar medical devices.(Projects subject to approval by law,Business activities can only be carried out after approval by relevant departments)

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.